<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210532</url>
  </required_header>
  <id_info>
    <org_study_id>DW1501-301</org_study_id>
    <nct_id>NCT03210532</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-blinded, Double-dummy, Phase 3 Clinical Trial to Evaluate
      the Efficacy and Safety of Combination Treatment with DW1501-R1+DW1501-R2 Versus DW1501-R1 or
      DW1501-R2+DW1501-R3 in Patients with Hypertension and Dyslipidemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of MSSBP(Mean Sit Systolic Blood Pressure) from baseline</measure>
    <time_frame>8-week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of LDL-C(Low Density Lipid Cholesterol) from baseline</measure>
    <time_frame>8-week</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>qd PO,Twynsta(telmisartan/amlodipine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan + Amlodipine + Rosuvastatin</intervention_name>
    <description>Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan + Amlodipine</intervention_name>
    <description>Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo</description>
    <arm_group_label>Reference 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan + Rosuvastatin</intervention_name>
    <description>Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo</description>
    <arm_group_label>Reference 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults both male and female who are ≥19,&lt;80 years old

          -  at screening, 140mmHg≤ SBP&lt;180mmHg &amp; 90mmHg≤ DBP&lt;110mmHg &amp; LDL-C≤250mg/dL &amp;
             triglyceride&lt;400mg/dL

        Exclusion Criteria:

          -  at screening, the difference BP of one-side arm is SBP ≥ 20mmHg and DBP ≥ 10mmHg

          -  secondary hypertension or secondary dyslipidemia

          -  patients who have uncontrolled diabetes melitus, hyper/hypothyroidism or cardiac
             disease

          -  women who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sevrance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

